Applications of 1-(3-Chlorphenyl)Piperazine in Industrial Manufacturing

As the direct manufacturer, we supply 1-(3-Chlorphenyl)Piperazine supporting established downstream markets that rely on consistent purity and regulatory compliance. Below, we detail its application in distinct industry scenarios, focusing on standardized usage, integration process, and resulting final product lines.

1. Pharmaceutical Intermediate for Antidepressant Synthesis

Active pharmaceutical ingredient (API) manufacturers utilize 1-(3-Chlorphenyl)Piperazine as a crucial intermediate when synthesizing selective serotonin reuptake inhibitors (SSRIs) and related compounds. The material participates in key condensation reactions essential for building the piperazine core linked to substituted aryl groups, which are characteristic of several serotonin-modulating APIs.

Industry compliance standards

• ICH Q7A: Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients
• USP–NF and Ph. Eur. standards on impurity control in API synthesis
• U.S. FDA 21 CFR Parts 210/211 for pharmaceutical manufacturing
• EU GMP Annex 13 for manufacturing of clinical trial materials

Typical usage ratio

• 0.6 to 1.2 molar equivalents per target molecule, adjusted based on targeted SSRI or analog structure and route yield optimization

Downstream process integration

• Introduced at the condensation or acylation stage with aryl halides during multi-step synthesis; purity and residual solvent levels monitored by HPLC in reaction streams

Final product types

• Paroxetine hydrochloride APIs
• Structural analogs of trazodone
• Other phenylpiperazine family antidepressants

2. Intermediate for Antipsychotic and Anxiolytic Agents

Specialty fine chemical plants employ 1-(3-Chlorphenyl)Piperazine in the synthesis of arylpiperazine-based antipsychotic or anxiolytic APIs. It functions as a key ring system provider, permitting subsequent selective N-alkylation, which is a defining feature in second-generation antipsychotic formulations and related CNS actives.

Industry compliance standards

• Pharmacopeia Standards: USP, JP, EP for finished pharmaceutical ingredients
• Current Good Manufacturing Practice (cGMP) for Intermediates—ICH Q7
• China Pharmacopoeia (ChP) guidelines for API synthesis
• REACH substance registration (EU)

Typical usage ratio

• 0.9–1.1 molar equivalents, with slight adjustment for yields in multi-step syntheses, particularly where N-substitution occurs

Downstream process integration

• Dosed in stirred reactors during initial coupling or reductive amination steps; downstream purification via column or crystallization guided by in-process analytical controls

Final product types

• Antipsychotic APIs such as aripiprazole intermediates
• Anxiolytic agents in the phenylpiperazine drug class
• Bulk pharmaceutical intermediates for export formulation plants

3. Precursor for Veterinary Pharmaceutical Intermediates

Veterinary API manufacturers leverage the chlorophenylpiperazine ring system as a building block for agents used in psychotropic or antiemetic veterinary medicines. It is handled in accordance with veterinary-specific process validations to assure purity, and is adapted for a variety of livestock and companion animal formulations.

Industry compliance standards

• Good Manufacturing Practice (GMP) for Veterinary Drugs—VICH GL35
• FDA CVM guidance for new animal drugs
• European Medicines Agency (EMA) VMP standards
• ISO 9001:2015 for chemical quality assurance

Typical usage ratio

• 0.85–1.3 molar equivalents, depending on target veterinary agent and multi-step formulation process control points

Downstream process integration

• Added during batch-wise step-growth reactions for veterinary piperazine-based molecules; followed by specific veterinary impurity profiling and batch release testing

Final product types

• Veterinary tranquilizer intermediates
• Veterinary antiemetic formulation bases
• Animal-use CNS medication raw materials

4. Reference Standard Material for Analytical Quality Control

Analytical and quality control laboratories at pharmaceutical companies require pure 1-(3-Chlorphenyl)Piperazine for use as a certified reference material (CRM) in method validation, impurity profiling, and routine batch analysis of phenylpiperazine series drugs. The quality of this material directly affects the precision and reliability of instrumental assay results throughout the drug development pipeline.

Industry compliance standards

• ISO/IEC 17025:2017 for testing and calibration laboratories
• USP General Chapter <1225> Validation of Compendial Procedures
• European Pharmacopoeia General Methods
• FDA guidance for industry: Analytical Procedures and Methods Validation for Drugs

Typical usage ratio

• Sub-milligram to low milligram quantities prepared per individual batch validation protocol, based on target method sensitivity and calibration requirements

Downstream process integration

• Applied during validation of HPLC, GC, or MS methods for both routine QC and regulatory dossier support; often prepared into standard solutions for lab-scale reference use

Final product types

• Certified secondary reference materials for API QC
• Calibration standards for analytical method development
• System suitability test kits for pharmaceutical manufacturing labs

5. Intermediate for Specialty Fine Chemical Derivatives

Producers of custom fine chemical intermediates supply this compound to downstream partners focused on innovative heterocyclic synthesis, particularly where substituted piperazine fragments prove indispensable in novel research compounds, industrial screening libraries, or advanced material prototypes. Each process follows strict documentation and traceability to support audit trails from raw material to final output.

Industry compliance standards

• REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) compliance for marketed substances in the EU
• ISO 9001:2015 for comprehensive lot traceability
• Local chemical safety and transport regulations (e.g., Dangerous Goods Regulations)
• Material Safety Data Sheet (MSDS) documentation standards

Typical usage ratio

• Adjusted case-by-case from 0.5–1.2 molar equivalents per proprietary syntheses, documented for process-specific yield optimization and customer project specifications

Downstream process integration

• Introduced in defined batch reactors, typically used in the key ring-forming or aryl substitution step, followed by purification via liquid-liquid extraction or column chromatography

Final product types

• Custom arylpiperazine intermediates for pharmaceutical R&D
• Specialty nitrogen heterocycles for chemical library screening
• Novel compound entities for advanced material science